David Liu has a new big idea: pro­teome edit­ing. It could one day shred tau, RAS and some of the worst dis­ease-caus­ing pro­teins

3 days ago
Discovery
In Focus

The 2021 top 100 bio­phar­ma in­vestors: As the pan­dem­ic hit and IPOs boomed, VCs swung in­to ac­tion like nev­er be­fore

4 days ago
Deals

Roivant par­lays a $450M chunk of eq­ui­ty in biotech buy­out, grab­bing a com­pu­ta­tion­al group to dri­ve dis­cov­ery work

Last week
Deals

Bio­phar­ma's suc­cess rate in bring­ing drugs to mar­ket has long been abysmal. Can new tools help rewrite that trou­bled past?

Last week
In Focus

The $1M IPO bonus, de­cent pay and a nice eq­ui­ty stake to mark the up­side: How does Mark McKen­na's comp pack­age stack up in the Nas­daq rush?

Last week
Financing
Bioregnum

Bio­phar­ma ex­ecs rou­tine­ly shun re­veal­ing the hard truth when it comes to RTFs. And some peo­ple at the FDA think that's a big prob­lem

3 weeks ago
Bioregnum
Regulatory

The Covid ef­fect has trig­gered some rad­i­cal changes to the top 50 bio­phar­ma list, bring­ing a whole new group of play­ers in­to the big league

3 weeks ago
Pharma

Ex­clu­sive: Af­ter four decades, one re­searcher's rad­i­cal HIV cure fi­nal­ly gets its shot

3 weeks ago
People
Startups

Francesco De Ru­ber­tis makes his lega­cy play, re­cruit­ing star ex­ecs and rolling up 10 biotech star­tups in­to a $250M gam­ble on cre­at­ing some­thing new in phar­ma

3 weeks ago
Startups

SR One re­cruits an IPO vet and sea­soned ops chief for the ven­ture team. And they have some prac­ti­cal ad­vice for you

4 weeks ago
People

The SPAC at­tack has just be­gun. And the Richard Bran­son deal is just the tip of the biotech ice­berg

4 weeks ago
Financing

The in­side sto­ry be­hind the fall of Lau­rie Glim­cher's big I/O start­up and the of­ten tense equa­tion of sci­ence and mon­ey

4 weeks ago
Startups

Af­ter rais­ing $465M, Kurt von Em­ster talks about mon­ey, bio­phar­ma and a new breed of in­vestor: 'The ris­ing tide is push­ing every­body in­to this sec­tor'

Last month
Deals

Ex­clu­sive: Third Rock­'s stealthy MO­MA Ther­a­peu­tics taps a long­time Mil­len­ni­um, Take­da vet as CEO

Last month
People

Is it time to stock up on wine? This pan­dem­ic could stretch out — and that has some ma­jor mar­ket im­pli­ca­tions

Last month
Bioregnum

As­traZeneca CEO Pas­cal So­ri­ot sev­ers an un­usu­al board con­nec­tion, steer­ing clear of con­flicts while re­tain­ing im­por­tant al­liances

Last month
Bioregnum

Af­ter 3 deaths rock the field, gene ther­a­py re­searchers con­tem­plate AAV's fu­ture

Last month
In Focus

Vivek Ra­maswamy and Matt Gline pen share­hold­er let­ters about the changes now un­der­way at Roivant

Last month
People

Scoop: Vivek Ra­maswamy is hand­ing the CEO job to a top lieu­tenant at Roivant — but he’s not ex­act­ly leav­ing the biotech scene

Last month
Bioregnum

Al­bireo just ad­vanced down to the 10-yard line at the FDA. And Ron Coop­er’s team is get­ting prepped for the next big play

Last month
Regulatory

What does $29B buy you in Big Phar­ma? In Glax­o­SmithK­line’s case, a whole lot of un­com­fort­able ques­tions about the pipeline

Last month
R&D

As coro­n­avirus vari­ants trig­ger new alarms, the NIH is putting an un­der-the-radar ‘next-gen’ vac­cine in­to PhI

Last month
Discovery

Pssst: That big Bio­haven Alzheimer's study? It was a bust. Even the sub­group analy­sis ex­ecs tout­ed was a flop

Last month
Bioregnum

Paint­ing by the num­bers, Sana founders carve up a gi­ant uni­corn-sized IPO — for a biotech that has­n't quite made it to the clin­ic

Last month
Financing
1234 Next page Last page